Investigational drug · Phase 2
MET233
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Obesity and Obesity-related Medical Conditions.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "MET233"
First trial start
2025
Mar 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MET233", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity and Obesity-related Medical Conditions
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "MET233" as an intervention, largest first.
- A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT06924320 · 201 participants · Start Mar 6, 2025 · Primary completion Sep 29, 2026
Drug: MET233 and MET097; MET097 · For: Obesity and Obesity-related Medical Conditions
Sites: Cypress, California
- A Study of MET233 in Individuals With Obesity or OverweightPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT07022977 · 145 participants · Start Nov 7, 2024 · Primary completion May 28, 2026
Drug: MET233; Placebo · For: Obesity and Overweight
Sites: Cypress, California
Newest research
PubMed records naming it or its code names, newest first.
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
Bailey CJ, Flatt PR, Conlon JM · Peptides 2026
- Cysteine Mutants of the Major Facilitator Superfamily-Type Transporter CcoA Provide Insight into Copper Import.
Khalfaoui-Hassani B, Trasnea PI, Steimle S, et al. · mBio 2021
- Uncovering the Transmembrane Metal Binding Site of the Novel Bacterial Major Facilitator Superfamily-Type Copper Importer CcoA.
Khalfaoui-Hassani B, Verissimo AF, Koch HG, et al. · mBio 2016
- Ligand binding pocket formed by evolutionarily conserved residues in the glucagon-like peptide-1 (GLP-1) receptor core domain.
Moon MJ, Lee YN, Park S, et al. · J Biol Chem 2015
- Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation.
Moon MJ, Kim HY, Park S, et al. · J Biol Chem 2012
- Attenuation of disease phenotype through alternative translation initiation in low-penetrance retinoblastoma.
Sánchez-Sánchez F, Ramírez-Castillejo C, Weekes DB, et al. · Hum Mutat 2007
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.